Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
14
HCM Quote, Financials, Valuation and Earnings
Last price:
$13.71
Seasonality move
:
-5.04%
Day range:
$13.20 - $13.76
52-week range:
$11.51 - $19.50
Dividend yield:
0%
P/E ratio:
4.92x
P/S ratio:
3.86x
P/B ratio:
2.33x
Volume:
101.6K
Avg. volume:
30.2K
1-year change:
-10.81%
Market cap:
$2.3B
Revenue:
$630.5M
EPS (TTM):
$2.66
Analysts' Opinion
-
Consensus RatingHUTCHMED (China) Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $22.58, HUTCHMED (China) Ltd. has an estimated upside of 68.92% from its current price of $13.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.47 representing 100% downside risk from its current price of $13.37.
Fair Value
-
According to the consensus of 12 analysts, HUTCHMED (China) Ltd. has 68.92% upside to fair value with a price target of $22.58 per share.
HCM vs. S&P 500
-
Over the past 5 trading days, HUTCHMED (China) Ltd. has underperformed the S&P 500 by -3.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
HUTCHMED (China) Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
HUTCHMED (China) Ltd. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter HUTCHMED (China) Ltd. reported revenues of --.
Earnings Growth
-
HUTCHMED (China) Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter HUTCHMED (China) Ltd. reported earnings per share of --.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
3.86x
EV / EBIT:
53.47x
EV / Revenue:
2.34x
PEG ratio (5yr expected):
-0.19x
EV / Free cash flow:
-23.58x
Price / Operating cash flow:
17.47x
Enterprise value / EBITDA:
36.29x
Gross Profit (TTM):
$266.5M
Return On Assets:
32.49%
Net Income Margin (TTM):
77.65%
Return On Equity:
50.64%
Return On Invested Capital:
46.32%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $204.4M | $218.3M | $264.1M | $55.2M | $75.8M | |
| Gross Profit | -- | $62.9M | -- | $12.9M | $17.5M | |
| Operating Income | -- | -$117M | -- | -$45.7M | -$80.5M | |
| EBITDA | -- | -$112.2M | -- | -$45.7M | -$80.5M | |
| Diluted EPS | -- | -$3.51 | -- | -$0.25 | -$0.42 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1B | $1.1B | $1B | $1.6B | |
| Total Assets | $1.3B | $1.2B | $1.3B | $1.3B | $1.8B | |
| Current Liabilities | $247.7M | $321.9M | $340.9M | $373.3M | $342.4M | |
| Total Liabilities | $259.2M | $342.5M | $497.5M | $508.9M | $534M | |
| Total Equity | $1B | $851.8M | $800M | $752M | $1.2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.6M | -$35.9M | -$99.7M | -- | -$49M | |
| Cash From Investing | -- | -$111.3M | -- | -- | -$315.9M | |
| Cash From Financing | -- | $89.4M | -- | -- | $605.1M | |
| Free Cash Flow | -- | -$44.3M | -- | -- | -- | |
HCM
Sector
Market Cap
$2.3B
$28.1M
Price % of 52-Week High
68.56%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-0.06%
-1.55%
1-Year Price Total Return
-10.81%
-19.36%
Beta (5-Year)
0.418
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$13.41
200-day SMA
Sell
Level
$15.22
Bollinger Bands (100)
Sell
Level
14.01 - 16.21
Chaikin Money Flow
Buy
Level
22.4M
20-day SMA
Sell
Level
$13.54
Relative Strength Index (RSI14)
Sell
Level
42.65
ADX Line
Sell
Level
29.45
Williams %R
Neutral
Level
-63.5769
50-day SMA
Sell
Level
$14.28
MACD (12, 26)
Sell
Level
-0.28
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
22.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.0555)
Buy
CA Score
(Annual)
Level (-0.0466)
Sell
Beneish M-Score
(Annual)
Level (-1.6283)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.075)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.
Stock Forecast FAQ
In the current month, HCM has received 9 Buy ratings 2 Hold ratings, and 1 Sell ratings. The HCM average analyst price target in the past 3 months is $22.58.
-
Where Will HUTCHMED (China) Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that HUTCHMED (China) Ltd. share price will rise to $22.58 per share over the next 12 months.
-
What Do Analysts Say About HUTCHMED (China) Ltd.?
Analysts are divided on their view about HUTCHMED (China) Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that HUTCHMED (China) Ltd. is a Sell and believe this share price will drop from its current level to $6.47.
-
What Is HUTCHMED (China) Ltd.'s Price Target?
The price target for HUTCHMED (China) Ltd. over the next 1-year time period is forecast to be $22.58 according to 12 Wall Street analysts, 9 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is HCM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for HUTCHMED (China) Ltd. is a Buy. 9 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HCM?
You can purchase shares of HUTCHMED (China) Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase HUTCHMED (China) Ltd. shares.
-
What Is The HUTCHMED (China) Ltd. Share Price Today?
HUTCHMED (China) Ltd. was last trading at $13.71 per share. This represents the most recent stock quote for HUTCHMED (China) Ltd.. Yesterday, HUTCHMED (China) Ltd. closed at $13.37 per share.
-
How To Buy HUTCHMED (China) Ltd. Stock Online?
In order to purchase HUTCHMED (China) Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HCM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HCM
Sector
P/E ratio
4.92x
24.09x
PEG ratio
-0.19x
-0.01x
P/B ratio
2.33x
1.83x
Price / LTM sales
3.86x
1.59x
Growth Metrics
HCM
Sector
Revenue growth
--
4.68%
Earnings growth
--
10.88%
Revenue (5-year growth)
25.21%
6.45%
Earnings forecast
--
-$0.18
Profitability
HCM
Sector
Profitability FY 2024
$281.5M
$3.6M
Return on invested capital
46.32%
-31.87%
Return on assets
32.49%
-28.18%
Return on equity
50.64%
-37.89%
Earnings Date
Last Earnings Date
Aug
7
Next Earnings Date
Mar
23
Estimated Next Earnings Date
Nov
6
Balance Sheet
HCM
Sector
Total cash
$1.4B
$26.2M
Short term investments
$682.2M
$25.7M
Total assets
$1.3B
$76.7M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
